# A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

> **NCT02678793** · PHASE2 · COMPLETED · sponsor: **Centrexion Therapeutics** · enrollment: 67 (actual)

## Conditions studied

- Morton's Neuroma

## Interventions

- **DRUG:** CNTX-4975

## Key facts

- **NCT ID:** NCT02678793
- **Lead sponsor:** Centrexion Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-12
- **Final completion:** 2017-03
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2018-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678793, "A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02678793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*